Medtech firms look to capitalize as obese youths turn to implantable treatments.
|
Swiss developer offers belly band that adjusts wirelessly.
|
U.S. government gives the okay to bring back silicone breast implants.
|
Pharma giant pays hefty premium for biotech firm to get into growing RNAi market.
|
Investors send the RNAi company’s stock down on news of follow-on offering.
|
Dow-funded research suggests silicone implants don’t increase risk of breast cancer.
|
Cosmetic maker Medicis teams with a European company to develop and market a competing anti-wrinkle treatment.
|
BSX files for merger clearance; Allergan extends Inamed offer; NUCRYST wound dressing goes to Europe.
|
The aesthetics products maker hopes to get marketing rights to cosmetic drug Reloxin.
|
The breast implant maker accepts offer from the manufacturer of Botox after rival suitor Medicis drops out.
|
Cephalon bids $360M for Zeneus; J&J still wants Guidant; Inamed’s board favors bid by Allergan.
|
AMDL Acquires Chinese Pharmas; Guidant Settles Suit; Medicis Presses Inamed; Healthcare Ups RFID Use.
|
The pharmaceutical company says no to acquisition offer after being outbid in its own attempt to purchase Inamed.
|
The cosmetic device maker leans toward $3.2-billion offer from Allergan over $2.8-billion bid from Medicis.
|
Botox maker ups Medicis’ bid for breast implant maker by offering $84 per share vs. $72.15 per share.
|
A new report shows that brand-name drug prices grew at almost twice the rate of inflation in the second quarter.
|
The CEO of Sirna Therapeutics discusses the first human trials of a drug candidate based on breakthrough RNAi technology.
|
Another use for Botox, another blow to Enron, and another Frankenfood for the EU.
|
Immunotox is developing the facial equivalent of PermaPress – and has the potential to unseat Botox as the socialite therapy of choice.
|